ABSTRACT. The inotropic, chronotropic, and vasodilatory effects of five commonly used cyclic adenosine 3',5'-monophosphate (cAMP)-modulating agents were evaluated. Hemodynamic functions were measured continuously in isoflurane-anesthetized cats during infus ion of the following: dobutamine (DOB; 2.5, 5 and 10 µg/kg/min; n=8), dopamine (DOP; 1.25, 2.5, 5 and 10 µg/kg/min; n=5), milrinone (MIL; 2.5, 5 and 10 µg/kg/min; n=8), 6-(3-dimethyl-aminopropionyl) forskolin hydrochloride (COL; 0.2, 0.4, 0.8, and 1.6 µg/kg/min; n=7), and bucladesine sodium (BUC; 10, 20, and 40 µg/kg/min; n=9). At the highest infusion rate, DOB and DOP produced the greatest positive inotropic (increase in left ventricular (LV) dP/dt = 89 ± 4% and 75 ± 6%, respectively) and chronotropic (increase in heart rate (HR) = 42 ± 4% and 22 ± 6%, respectively) effects. MIL and COL produced similar albeit less pronounced positive inotropic (increase in LV dP/dt = 18 ± 3% and 22 ± 6%, respectively) and chronotropic (increase in HR = 13 ± 4% and 21 ± 4%, respectively) effects. Both also had significant vasodilatory effects (decrease in peripheral resistance (PR) = -30 ± 2% and -35 ± 7%, respectively). In contrast, BUC produced only vasodilatation (decrease in PR = -33 ± 6%). Hence, MIL, COL, and BUC had significant vasodilatory effects and less-pronounced inotropic effects than the catecholamines DOB and DOP. The vasodilatory effects of non-catecholamine drugs for treatment of congestive heart failure should translate into beneficial decreases in both pre-load and after-load. In contrast, the strong inotropic effects of DOB and DOP should be beneficial in the treatment of acute heart failure and anesthetic crisis.
Sympathomimetic agents such as dobutamine (DOB), dopamine (DOP) and epinephrine, enhance myocardial contraction via β-adrenergic stimulation. The management of acute or chronic heart failure requires the support of hemodynamic and cardiac functions with catecholamines. Unfortunately, β-adrenergic receptor down-regulation is frequently observed during heart failure [17] . On the other hand, other cardiotonic agents enhance cyclic adenosine 3',5'-monophosphate (cAMP) levels without β-adrenergic receptor stimulation: the phosphodiesterase (PDE) III inhibitor milrinone (MIL) inhibits cAMP degradation and, thus, increases its intracellular concentration [15] ; 6-(3-dimethylaminopropionyl) forskolin hydrochloride (COL), which is a potent water-soluble forskolin derivative, increases intracellular cAMP by stimulating adenylate cyclase activity [11, 29] ; bucladesine sodium (BUC) is membrane permeable cAMP [12, 22] . These agents produce inotropic and chronotropic effects on the heart and induce vascular relaxation by modulating intracellular cAMP levels.
The use of inotropic agents is also necessary during surgery, when anesthetic side effects, hemorrhage, bradycardia and precipitous decreases in blood pressure are encountered.
Since it is often difficult to choose the most appropriate medication in a particular situation, a better understanding of the characteristics of these agents is required. However, there is no report available for these agents in cats.
Thus, in this study, the chronotropic, inotropic, and vasodilatory effects of five agents that are commonly used in clinical settings were investigated. This study was aimed to observe the changes in cardiac and hemodynamic functions in normal isoflurane-anesthetized cats. Our findings apply to situations involving anesthetic-induced hemodynamic perturbations, as well as to instances of declining cardiac function in the conscious state.
MATERIALS AND METHODS
This study was conducted followed the Guidelines for Institutional Laboratory Animal Care and Use at the School of Veterinary Medicine and Animal Science at Kitasato University, Japan.
Nineteen adult mongrel cats of either sexes, weighing 2.5 to 4.0 kg and fed commercial dry food (Hill's Japan, Tokyo, Japan) were used in the study. Following induction of anesthesia with isoflurane (1.5 to 2.0% vol) and ventilation by spontaneous respiration, a fluid-filled Tygon catheter (Norton Elastic and Synthetic Division, OH, U.S.A.) was implanted via the femoral artery into the descending thoracic aorta. A 1.8F Millar catheter tip pressure transducer (Millar Industrial, U.S.A.) was passed through the left carotid artery and aortic valve, implanted in the left ventricular (LV), and used to continuously monitor LV pressure and maximum rate of pressure development (dP/dt). A median laparotomy (about 10 cm in long) was made to permit placement of a blood-flow probe (Transonic Systems, NY, U.S.A.) around the abdominal aorta just above the renal artery, for continuous monitoring of blood-flow. The cathe-ters and leads were externalized and the laparotomy was closed. The catheter in the descending thoracic aorta was connected to strain-gauge manometers (Nihon Kohden, Tokyo, Japan) for arterial blood pressure measurements. Heart rate (HR) was determined from electrocardiogram (ECG) recordings.
Hemodynamic measurements were recorded with cats in right lateral recumbency. After completion of pre-surgical procedures, a 15-to 20-min stabilization period was provided to establish stable baseline conditions for HR, blood pressure, LV dP/dt, and blood flow.
Aortic and LV pressures, LV dP/dt, 1/2tau (indicated isovolumetric relaxation phase of left ventricular as index of diastolic function), HR, and ejection time (ET: duration of aortic blood flow) were digitized at 500 Hz and analyzed on a computer-based system (Notocord, Croissy, France). LV end-diastole was defined as the point of onset of positive LV dP/dt, whereas LV end-systole was defined as the point of peak-negative LV dP/dt. Peripheral resistance (PR) was calculated as the mean arterial pressure divided by the abdominal aortic blood flow.
Five cardiotonic drugs dobutamine (DOB) (Shionogi & Co., Osaka, Japan), dopamine (DOP) (Nikken Chemicals, Tokyo, Japan), milrinone (MIL) (Yamanouchi Pharmaceutical, Tokyo, Japan), 6-(3-dimethyl-aminopropionyl) forskolin hydrochloride (COL) (Nippon Kayaku, Tokyo, Japan) and bucladesine sodium (BUC) (Daiichi Pharmaceutical, Tokyo, Japan) were tested, using drug solutions that were prepared in normal saline immediately before each experiment. The experimental drug was infused for 5-10 min through the saphenous vein. DOB (n=8) and MIL (n=8) were administered at rates of 2.5, 5 and 10 µg/kg/min, while DOP (n=5) was administered at 1.25, 2.5, 5 and 10 µg/kg/ min. COL (n=7) was administered at 0.2, 0.4, 0.8, and 1.6 µg/kg/min; for BUC (n=9), the rates were 10, 20, and 40 µg/ kg/min, respectively. The dosage of each agent was decided by preliminary experiments in cats which referred to literatures in dogs [14, 26] . Hemodynamic measurements were recorded continuously during drug infusion.
In the case of DOB and DOP, which undergo rapid clearance [20, 21] , their infusion was followed by a 30-to 60-min washout phase prior to infusion of the next drug. Because of their long duration of action [11, 21] , MIL and COL were infused different cats. Baseline hemodynamic measurement was recorded before infusion of each agent.
Data were expressed as mean ± SE. The effects of each drug at the different dose levels were analyzed by repeatedmeasures with Super ANOVA, followed by post-hoc testing. The effects of the five agents were analyzed by oneway ANOVA, followed by post-hoc testing. A value of p<0.05 was considered to be statistically significant.
RESULTS

Dobutamine:
In cats infused with DOB, LV systolic pressure, LV dP/dt, and HR increased significantly with increasing dose of DOB ( Fig. 1 , Table 1 ). Mean arterial pressure (MAP) increased with 2.5 and 5 µg/kg/min infusions but returned to baseline values at 10 µg/kg/min. Preload, as assessed by changes in LV end-diastolic pressure, fell slightly or was unchanged. At 10 µg/kg/min, abdominal aortic flow increased by 56 ± 17%, PR decreased by 27 ± 8%, and LV diastolic function as 1/2tau improved. Dopamine: DOP produced dose-dependent increases in LV systolic pressure, LV dP/dt and HR. MAP did not change at low infusion rates (1.25 and 2.5 µg/kg/min), but increased significantly (18 ± 8%; p<0.05) at the highest infusion rate (10 µg/kg/min). LV end-diastolic pressure was unchanged, but LV diastolic function as 1/2tau improved ( Table 2 ). Blood flow in the abdominal aorta tended to increase, as did PR.
Milrinone: MIL produced dose-dependent increases in LV dP/dt and HR, but MAP decreased. LV end-diastolic pressures fell slightly. Abdominal aortic blood flow increased by 17 ± 5%, and PR decreased by 30 ± 2% at the highest dose (10 µg/kg/min). LV diastolic function as 1/ 2tau improved (Table 3) .
6-(3-dimethyl-aminopropionyl) forskolin hydrochloride: COL produced dose-dependent increases in LV dP/dt and HR decreases in MAP; LV end-diastolic pressures fell slightly. Abdominal aortic blood flow increased by 30 ± 7% at the highest dose (1.6 µg/kg/min). PR decreased by 35 ± 4% and LV diastolic function as 1/2tau improved (Table 4) .
Bucladesine sodium: MAP and LV systolic pressure decreased significantly at each dose in cats given BUC. Reduced after-load was demonstrated by increases in abdominal aortic blood flow and decreases in PR. LV dP/dt and HR showed no positive inotropic or chronotropic effects. Neither LV systolic nor diastolic function were affected by BUC (Table 5) .
DISCUSSION
Long-term use of inotropic agents leads to increased mortality among patients with severe chronic heart failure [23] due to the effects of catecholamines in increasing cardiac output and myocardial oxygen consumption [27] . Nonetheless, although chronic catecholamine stimulation is deleterious for patients with heart failure, it is beneficial in the support of cardiac function in decompensated heart failure. However, β-receptor down-regulation is frequently observed in cases of heart failure [4, 5, 7] , and severe heart failure occasionally does not respond to catecholamine treatment. Several types of novel cardiac agents, such as MIL, COL, and BUC, have been developed but their effects in cats have yet to be reported.
The present study compared the cardiovascular effects of DOB, DOP, MIL, COL and BUC in cats that were anesthetized with isoflurane. Isoflurane has been shown to produce dose-dependent decreases in systemic arterial pressure, cardiac output, LV dP/dt, vascular resistance and oxygen consumption [10, 28, 31] . Merin et al. reported that compared to the values measured during consciousness, HR and coronary blood flow are increased under isoflurane anesthesia in Heart rate (beats/min) 8 113 ± 4 +9 ± 2 * +23 ± 3 * +42 ± 4 * Mean arterial pressure (mmHg) 8 85 ± 6 + 1 0 ± 3 * +11 ± 4 * +5 ± 6 LV peak systolic pressure (mmHg) 8 104 ± 5 + 1 1 ± 2* +15 ± 2* +18 ± 3* LV end-diastolic pressure (mmHg) 8 10 ± 2 -4 ± 5 -1 4 ± 11 -8 ± 16 LV dP/dt (mmHg/sec) 8 2,368 ± 218 +33 ± 3* +61 ± 3* +89 ± 4* 1/2tau 8 23 ± 1 -1 0 ± 1* -20 ± 3* -32 ± 2* Abdominal aortic blood flow (ml/min) 8 59 ± 10 +28 ± 10* +48 ± 15* +56 ± 17* Peripheral resistance (mmHg/ml·min) 8 1.9 ± 0.6 -12 ± 7 -2 0 ± 8 -2 7 ± 8
Values are means ± SE. LV: left ventricular. dP/dt: first derivative of LV pressure. * p<0.05, significant changes from baseline values. Heart rate (beats/min) 5 121 ± 7 +1 ± 2 +4 ± 2 +10 ± 3 + 2 2 ± 6* Mean arterial pressure (mmHg) 5 96 ± 6 -4 ± 3 0 ± 3 + 7 ± 6 + 1 8 ± 8* LV peak systolic pressure (mmHg) 5 103 ± 9 -2 ± 2 +8 ± 4 +28 ± 9* +55 ± 18* LV end-diastolic pressure (mmHg) 5 9 ± 2 -1 ± 6 0 ± 9 -3 ± 9 -1 0 ± 12 LV dP/dt (mmHg/sec) 5 2,908 ± 266 0 ± 2 +11 ± 3* +36 ± 4* +75 ± 6* 1/2tau 5 18 ± 1 -8 ± 9 -7 ± 10 -9 ± 10 -16 ± 10* Abdominal aortic blood flow (ml/min) 5 38 ± 5 +18 ± 9 +18 ± 22 +10 ± 33 +10 ± 40 Peripheral resistance (mmHg/ml·min) 5 2.
Values are means ± SE. LV: left ventricular dP/dt: first derivative of LV pressure. * p<0.05, significant changes from baseline values.
dogs [19] . Further, Hodgson et al. indicated that isoflurane causes hypotension and hypercapnia at 2.0 the minimal alveolar concentration (MAC), whereas at 1.3 MAC, isoflurane produces minimal cardiopulmonary depression, especially in healthy cats that are allowed to breathe spontaneously [10] . Under these present studies, this study compared each inotoropic agent at close to 1.3 MAC in isoflurane-anesthetized cats, and would be able to evaluate at accurate cardiovascular performance. Our findings highlight the compounds that are likely to be beneficial for cardiac support in anesthetized cats and in cats undergoing heart failure or shock. DOB produced dose-dependent positive chronotropic and inotropic effects, with no apparent effect on MAP. Thus, DOB can be useful for stimulating cardiac contraction under various conditions, such as decompensation, and depression of cardiac function due to anesthetics.
Like DOB, DOP produced positive chronotropic and inotropic effects and improvement of diastolic function. It significantly increased MAP (+18 ± 8%) and PR (+72 ± 62%) at the highest dose (10 µg/kg/min). Therefore, high-dose DOP appears to be useful in treating significant hemorrhage Heart rate (beats/min) 8 117 ± 7 +2 ± 1 +9 ± 3 * +13 ± 4 * Mean arterial pressure (mmHg) 8 60 ± 6 -5 ± 1 * +12 ± 2 * +18 ± 3 * LV peak systolic pressure (mmHg) 8 85 ± 5 + 4 ± 3 + 2 ± 4 0 ± 4 LV end-diastolic pressure (mmHg) 8 8 ± 1 -5 ± 7 -8 ± 11 -16 ± 8 LV dP/dt (mmHg/sec) 8 2,282 ± 178 +8 ± 2* +13 ± 2* +18 ± 3* 1/2tau 8 23 ± 3 -6 ± 3 -1 0 ± 4 -1 4 ± 4* Abdominal aortic blood flow (ml/min) 8 45 ± 7 + 4 ± 1* +9 ± 2* +17 ± 5* Peripheral resistance (mmHg/ml·min) 8 1.
Values are means ± SE. LV: left ventricular. dP/dt: first derivative of LV pressure. * p<0.05, significant changes from baseline values. Table 4 . Effects of forskolin hydrochloride on hemodynamics Heart rate (beats/min) 7 117 ± 7 + 3 ± 3 +6 ± 3 +10 ± 5 +21 ± 4* Mean arterial pressure (mmHg) 7 77 ± 5 -4 ± 2 -6 ± 3 -13 ± 4 -16 ± 4* LV peak systolic pressure (mmHg) 7 95
2,385 ± 203 +4 ± 3 +9 ± 3* +11 ± 3* +22 ± 6* 1/2tau 7 2 0 ± 3 -1 ± 2 -4 ± 2 -7 ± 2 -9 ± 3* Abdominal aortic blood flow (ml/min) 7 42 ± 8 +11 ± 4 +16 ± 4 +21 ± 6* +30 ± 7* Peripheral resistance (mmHg/ml·min) 7 2.3 ± 0.5 -13 ± 3* -18 ± 3* +30 ± 3* -35 ± 4*
Values are means ± SE. LV: left ventricular dP/dt: first derivative of LV pressure. * p<0.05, significant changes from baseline values. Table 5 . Effects of bucladesine sodium on hemodynamics
Bucladesine sodium (µg/kg/min) % change from baseline n B ase li ne 10 2 0 4 0
Heart rate (beats/min) 9 112 ± 8 0 ± 1 -2 ± 2 -2 ± 2 Mean arterial pressure (mmHg) 9 82 ± 6 -7 ± 2 * -13 ± 3 * -18 ± 4 * LV peak systolic pressure (mmHg) 9 100 ± 7 -4 ± 2 -7 ± 2* -11 ± 3* LV end-diastolic pressure (mmHg) 9 12 ± 1 -7 ± 4 -4 ± 7 -1 ± 8 LV dP/dt (mmHg/sec) 9 2,434 ± 175 -4 ± 2 -7 ± 3* -10 ± 3* 1/2tau 9 2 1 ± 3 -3 ± 2 -2 ± 3 -2 ± 3 Abdominal aortic blood flow (ml/min) 9 50 ± 10 +13 ± 7* +17 ± 8* +32 ± 16* Peripheral resistance (mmHg/ml·min) 9 2.3 ± 0.6 -15 ± 5* -23 ± 5* -33 ± 6
Values are means ± SE. LV: left ventricular. dP/dt: first derivative of LV pressure. * p<0.05, significant changes from baseline values.
or severe hypotension. On the other hand, since low doses of DOP promoted renal and mesenteric artery vasodilatation, causing increased abdominal aortic blood flow and diuresis [3] , DOP may be beneficial in the preservation of organ function and blood flow in states of anesthesia or low cardiac output. MIL, COL and BUC have been used as second-line inotropic agents. These drugs produce positive inotropic, chronotropic and vasodilatory effects, together with increased coronary blood flow [11, 12, 32] . Compared with DOB and DOP, MIL and COL have only slight effects on LV myocardial contractility. Further, Hirasawa et al. suggested they also have marked vasodilatory effects, which might depress blood pressure and induce tachycardia or arrhythmia [9] . MIL specifically inhibits phosphodiesterase III, resulting in increased myocardial contraction and vascular dilatation through increased intracellular cAMP levels [1, 18] . COL also augments intracellular cAMP in vascular smooth muscle and may have an even greater effect in ventricular muscle [13, 33] . Compared with the catecholamines, these agents have lower inotropic activities and causes less improvement of diastolic function, but greater hypotensive effects. Because anesthesia with isoflurane tends to induce hypotension, these agents would not usually be used during isoflurane anesthesia. Although the experimental condition was different, similar results were reported in dogs [11, 24, 26] . Konstom and Cody showed that MIL has a longer plasma elimination half-life than the β-adrenergic agonist DOB [15] , and it has a complementary effect. Colucci et al. reported that combined use of MIL and DOB may result in significantly better hemodynamic performance than achieved with either agent alone in human [6] . Through due to these results, MIL and COL would be expected to yield a similar outcome in cats. Since depressed catecholamine response, secondary to β-receptor down-regulation, is observed in heart failure, MIL and COL (sometimes combined with catecholamine) may be of value in treating heart failure. BUC was reported to produce positive inotropic and chronotropic effects, which were associated with increased coronary flow at dogs, cats, rats, guinea pigs and rabbits in vitro [12, 16, 30] . In contrast, it was also reported that BUC produced only slight and variable changes in cardiovascular performance at dogs in vivo and rats in vitro [8, 25] . Both studies reported increases in both coronary blood flow and vasodilatation, although no positive inotropic or chronotropic effects were observed. The results of the present study are consistent with these findings. BUC may thus be categorized as a vasodilator rather than as an inotrope.
In conclusion, this study revealed that cardiovascular effects of these agents in cats were consistent with other animals and human. When treating heart failure or anestheticinduced cardiovascular problems it is necessary to anticipate the outcome: left ventricular myocardial contractility should increase or pre-load and PR should decrease. Drugs that increase inotropic activity by β-receptor stimulation, and those that increase intracellular cAMP through various mechanisms, can potentiate arrhythmias of various origins [2] . However, since no arrhythmia was observed in our study, the drugs investigated might be useful in cases of depressed cardiac function or inducing anesthesia without chronic heart failure. On the other hand, since MIL, COL, and BUC have significant vasodilatory effects, these can be used to decrease pre-load and after-load in congestive heart failure. DOB and DOP, with their potent inotropic activities, can be beneficial in cases of heart failure and anesthetic complications in cats.
